Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
1,204 results
  • A subset of colorectal cancers with cross-sensitivity to olaparib and oxaliplatin. [Journal Article]
    Clin Cancer Res 2019Arena S, Corti G, … Bardelli A
  • CONCLUSIONS: These results indicate that a CRC subset characterized by poor prognosis and limited therapeutic options is vulnerable to PARP inhibition and suggest that PDO-based drug-screening assays can be used to identify CRC patients likely to benefit from olaparib. As mCRC patients almost invariably receive therapies based on oxaliplatin, 'maintenance' treatment with PARP inhibitors warrants further clinical investigation.
  • Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations. [Review]
    Drugs 2019Jerez Y, Márquez-Rodas I, … López-Tarruella S
  • The poly-(ADP-ribose) polymerase (PARP) inhibitors olaparib and talazoparib, have recently been approved for use in patients with metastatic breast cancer (BC) and germline BRCA 1 or 2 mutations due to improved progression-free survival compared to chemotherapy. An increasing number of clinical trials are evaluating the role of PARP inhibitors (PARPi) in BC, alone and in combination with other th…
  • Tankyrase promotes primary precursor miRNA processing to precursor miRNA. [Journal Article]
    Biochem Biophys Res Commun 2019Mizutani A, Seimiya H
  • Tankyrases (TNKS and TNKS2) are members of poly(ADP-ribose) polymerase (PARP) family proteins. Tankyrase has multiple ankyrin repeat cluster (ARC) domains, which recognize the tankyrase-binding motifs in proteins including the telomeric protein, TRF1 and Wnt signal regulators, AXINs. However, the functional significance of tankyrase interaction with many other putative binding proteins remains un…
New Search Next